FAQs

General

How many people does AstraZeneca employ worldwide?

We employ approximately 61,500 people:

  • 38% in Europe (including Russia, Middle East & Africa)
  • 29% in the Americas
  • 33% in Asia-Pacific.

How many shares does AstraZeneca have outstanding?

The total number of shares in issue at 31 December 2015 was 1,264 million.

On what stock exchange is AstraZeneca traded and what is the stock symbol?

AstraZeneca is traded on the London, New York and Stockholm stock exchanges. The symbol is AZN in all three markets.

What accounting convention does AstraZeneca adhere to?

AstraZeneca adheres to the International Financial Reporting Standards (IFRS) and International Accounting Standards (IAS) with appropriate conversion to US GAAP being shown in our financial statements.

What is AstraZeneca's current debt rating?

Moody's :

Long-term: A3 stable, Short term: P-2.

Standard & Poor's

Long-term: A- stable, Short-term: A-2

What is AstraZeneca's CUSIP number for its ADRs traded on the New York Stock Exchange?

046353108

What is AstraZeneca's official accounting currency?

AstraZeneca reports in US dollars.

When is AstraZeneca's next earnings release?

AstraZeneca will announce its second quarter results on Thursday 28 July 2016.

When is AstraZeneca’s next Annual General Meeting?

AstraZeneca holds its Annual General Meeting (AGM) each year in London during April.

The Notice of AGM will usually be sent to shareholders a month in advance.

When was AstraZeneca PLC formed?


AstraZeneca was formed on 6 April 1999 through the merger of Astra AB of Sweden and Zeneca PLC of the United Kingdom. 

Where can I find historical financial information on AstraZeneca?

This information can be found in the financial results section.

When will I receive my next dividend payment?

For information on dividends, please see the Dividends section of the FAQs.

Dividend policy

Dividends

Can AstraZeneca pay my dividends directly into my bank or building society account?

Yes, it is possible to have your dividends paid directly into your bank or building society.

If your shares are held by a broker or nominee please contact them directly.

If you are a registered shareholder please contact the following:  

UK shareholders can click here to obtain the relevant form from the Equiniti Shareview website. Alternatively, contact Equiniti to request a form

  • US shareholders should contact Citibank Shareholder Services at 1-888-697-8018.
  • Swedish shareholders should contact your personal broker or if you hold a VPC account contact the VPC on +46 (0) 8 402 9000, alternatively contact Euroclear.

Contact details for Equiniti, Citibank and Euroclear can be found here.

Does AstraZeneca have a dividend re-investment plan?

At present AstraZeneca does not have a dividend re-investment plan.

I am a non-taxpayer; can I have my AstraZeneca dividends paid gross?

No, it is not possible to have your dividends paid gross.

Where can I find dividend information?

Please visit our dividend policy.

In which currency will my dividend be paid?

AstraZeneca pays the dividend in the currency corresponding to where the shares are listed.

Can I choose to receive my dividend in a different currency?

Holders of Ordinary Shares listed in London may be able to use Equiniti’s Overseas Payment Service to receive the dividend in a currency other than GBP. Contact Equiniti for details.

Registered shareholders

My personal details have changed - whom do I contact?

Who do I contact to:

  • request information on my account?
  • transfer stock?
  • request a share certificate replacement?

This will depend on where your shares are held:

If your shares are held by a broker or nominee please contact them directly.

If you are a registered shareholder please contact the following:

    UK shareholders should contact Equiniti.
    US shareholders should contact Citibank Shareholder Services at 1-888-697-8018.
    Swedish shareholders should contact your personal broker or if you hold a VPC account contact the VPC on +46 (0) 8 402 9000.

    Contact details for Equiniti and Citibank can be found on the Investor information page under Investor resources.
     

Mergers/demergers

I am a UK shareholder. How do I allocate my cost basis of AstraZeneca shares to my Syngenta distribution?

Please follow the link below to a summary of dividends paid in the form of Syngenta shares.

View UK cost basis information opens in a new window.

I am a US shareholder. How do I allocate my cost basis of AstraZeneca shares to my Syngenta distribution?

Please follow the link below to a summary of dividends paid in the form of Syngenta shares.

View US cost basis information opens in a new window.

I still hold Astra AB shares. What course of action should I take?

View a letter to Astra AB shareholders opens in a new window.

A legal representative, Peter Haglund, has been appointed to act on behalf of minority shareholders. He can be contacted at Advokatfirman Sodermark, Box 14055, SE 104 40 Stockholm, Sweden, telephone +46 8 670 57 50 and fax +46 8 663 67 20.

What was the closing price of AstraZeneca PLC shares on its first trading day?

On 6 April 1999 (the first trading day of AstraZeneca PLC) the closing price was GBP 29.46.

What was the value of Zeneca shares when it demerged from ICI?

Shares in Zeneca Group PLC acquired on demerger from ICI will be treated as having a base cost for capital gains tax purposes ascertained by reference to the values of Zeneca and ICI shares on 1 June 1993 calculated in accordance with the provisions of Section 272 of the Taxation of Chargeable Gains Act 1992. The base cost of any holding of ICI Shares on that date will be adjusted on the same basis.

The relevant prices on The London Stock Exchange on 1 June 1993 were:

Zeneca - 625.75p and ICI - 631.75p

The base cost of the pre-merger ICI Shares were therefore split between the post-demerger Zeneca and ICI Shares in the following proportions:

Zeneca - 0.49761 and ICI - 0.50239

When Astra AB and Zeneca Group PLC merged how were the shares split / merged?

Astra AB and Zeneca Group PLC shares were merged on 6th April 1999.
1 Astra share : 0.5045 AstraZeneca share
1 Zeneca share : 1 AstraZeneca share

When did AstraZeneca demerge its agrochemical business?

AstraZeneca demerged its agrochemical business on 13 November 2000.

ADSs

What is an ADS/ADR?

In the US, AstraZeneca’s Ordinary Shares are traded in the form of American Depositary Shares (ADSs), evidenced by American Depositary Receipts (ADRs), which are traded on the New York Stock Exchange under ticker symbol AZN. An ADS is a US dollar denominated form of equity ownership representing AstraZeneca’s underlying Ordinary Shares on deposit in the United Kingdom, and it confers the rights arising out of the underlying Ordinary Share including the right to vote at and attend general meetings of AstraZeneca and the right to receive dividends in US dollars.

What is the ADS ratio change and when will it take effect?

Historically one ADS has been equal to one Ordinary Share of AstraZeneca, a 1:1 ratio.

On 27 July 2015, a ratio change was effected so that two ADSs became equal to one Ordinary Share, a ratio of 2:1. ADS holders on the record date at the close of business on 22 July 2015 New York time received a distribution of one additional ADS for every one ADS held. No action was required by you to effect this change. These changes brought the AstraZeneca ADS price broadly in line with the market average and, as the ADS price reduced, it is thought that  the shares should be more attractive to individual shareholders and liquidity improved.
  

How has the ADS ratio change affected my shareholding in AstraZeneca?

The number of ADSs that were registered in your name at the close of business on 22 July 2015 New York time were doubled. While it is not possible to isolate the effect of the ratio change on the price of AstraZeneca’s ADSs from all the factors that affect the price, it is believed that the immediate effect was a reduction in price to approximately one-half of that prevailing immediately before the ratio change. The reduction in price, when coupled with the doubling of the ADSs held in your name should leave the value of your holding approximately the same immediately after, as it had been immediately before, the ratio change.
 

Will the ADS ratio change affect my dividends?

No. While the ratio change resulted in a halving of what would otherwise have been the dividend rate per share, your aggregate dividend remains the same as it would otherwise have been because your ADS holding has doubled.
 

Will I be subject to US federal income tax upon receipt of additional ADSs as a result of the ratio change?

No. The ratio change should have no US federal income tax implications for ADS holders, except that such holders should allocate to each additional ADS half of the holder’s tax basis in the original ADS with respect to which the additional ADS was received. If you hold ADSs as capital assets for US federal income tax purposes, your holding period for an additional ADS for capital gains tax purposes should include your holding period for the existing ADS with respect to which the additional ADS is received.
 

Are ADS holders charged a dividend fee?

Yes, beginning with the second interim dividend paid on 23 March 2015, holders of American Depositary Shares (ADSs) will be charged a total of $0.03 (3 cents) per ADS annually to cover costs related to the ADS programme. A fee of $0.01 (1 cent) will be deducted from the first interim dividend which is typically announced with second quarter and half year results and paid in September each year, and a fee of $0.02 (2 cents) will be deducted from the second interim dividend which is typically announced with fourth quarter and full year results and paid in March each year. 

Do other companies charge a dividend fee on their ADSs?

Approximately 70% of the companies within the FTSE100 that have an ADR/ADS programme charge dividend fees. The fees range from $0.01 (1 cent) to $0.04 (4 cents) per ADS per annum. Of those companies that declared a dividend in 2013, the average dividend fee as a percentage of the gross dividend declared was approximately 6.5%. AstraZeneca’s recently introduced dividend fee as a percentage of its dividends declared in respect of 2015 ($1.40 per ADR) was approximately 2.1%.

  • Annual Reports

    Our Annual Report provides a wide range of information about our global business.

  • Our Pipeline

    Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.

  • Shareholder FAQs

    Answers to frequently asked shareholder questions.